Last reviewed · How we verify
NCT06706466
Evaluate the Prognostic Significance of Changes in the Systemic Immune-Inflammation Index in Patients with AGC Treated with ICI Therapy.
trial testing observational study in Immunotherapy Gastrict Cancer in 410 participants. Completed in 1 May 2024.
31 December 2021
Quick facts
| Lead sponsor | Chang-Ming Huang, Prof. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 410 |
| Start date | 1 January 2018 |
| Primary completion | 31 December 2021 |
| Estimated completion | 1 May 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- observational study — full drug profile →
Conditions studied
- Immunotherapy Gastrict Cancer — all drugs for Immunotherapy Gastrict Cancer →
- Inflammation Biomarkers — all drugs for Inflammation Biomarkers →
- Gastric Cancers — all drugs for Gastric Cancers →
Sponsor
Chang-Ming Huang, Prof. — full company profile →
Who can join
Adults 18 to 80, any sex, with Immunotherapy Gastrict Cancer or Inflammation Biomarkers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The SIIR during neoadjuvant therapy can serve as a specific biomarker for predicting the efficacy of immunotherapy in patients with advanced gastric cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06706466
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of observational study
Trials testing the same drug.
- NCT07497139 — Sepsis Induced Myocardial Injury in Critically Ill Children · not yet recruiting
- NCT07379567 — BREVOC Study: Exhaled VOCs for High-Risk Chest Pain in the ED · not yet recruiting
- NCT07391007 — Integrated Clinical-molecular Risk Stratification to Early Recurrence in Colorectal Liver Metastases · not yet recruiting
- NCT07372183 — Wound Healing Following Extraction and Ridge Preservation in Smokers and Non-smokers · not yet recruiting
- NCT07310186 — Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy · not yet recruiting
Other recruiting trials for Immunotherapy Gastrict Cancer
Currently open trials in the same condition.
- NCT05699655 — Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann I · Phase 2, PHASE3 · recruiting
Other Chang-Ming Huang, Prof. trials
Trials by the same sponsor.
- NCT06716593 — Trajectory of Body Composition Identifies LAGC with Cachexia Following NACT · completed
- NCT06573307 — Hematological Dynamic Scores for Predicting Survival and Treatment Response for Advanced Gastric Cancer After Neoadjuvan · completed
- NCT06548464 — Interpretable Machine Learning Models for Prognosis in Gastric Cancer Patients · completed
- NCT06673472 — Comparison of Long-term Outcomes Between Upfront Surgery and Neoadjuvant Therapy Followed by Surgery in Patients with No · completed
- NCT06393153 — Model for Prognosis of Elderly Gastric Cancer Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06706466 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chang-Ming Huang, Prof.
- Last refreshed: 26 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06706466.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing